AI Summary
OpenAI has introduced GPT-Rosalind, an AI model designed to enhance drug discovery processes. This initiative reflects the growing interest among tech companies in applying AI to life sciences, with initial users including major pharmaceutical firms and research institutions.
- OpenAI has launched an early version of an AI model called GPT-Rosalind aimed at drug discovery.
- The model is designed to assist in life sciences research by analyzing large data sets and translating scientific studies into healthcare applications.
- GPT-Rosalind will initially be available as a research preview to select business customers, including Amgen Inc., Moderna Inc., and the Allen Institute.
openaidrug discoveryai modelscientific breakthroughstechnology